ArticlePsychiatric services (Washington, D.C.)2008
Who are the new users of antipsychotic medications?
Article in Psychiatric services (Washington, D.C.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Second-generation antipsychotics for major depressive disorder and dysthymia.The Cochrane database of systematic reviews · 2010Pooled it
- Off-label policy through the lens of trazodone usage and spending in the United States.Health affairs scholar · 2025Article
- Influences of race and clinical variables on psychiatric genetic research participation: Results from a schizophrenia sample.PloS one · 2023Article
- Characteristics and predictors of off-label use of antipsychotics in general population sample.Acta psychiatrica Scandinavica · 2022Article
- Impacts of Psychopharmaceuticals on the Neurodevelopment of Aquatic Wildlife: A Call for Increased Knowledge Exchange across Disciplines to Highlight Implications for Human Health.International journal of environmental research and public health · 2021Article
- Most Second-Generation Antipsychotic Prescriptions in Community Practice Are Neither FDA-Approved nor Within Prescribing Guideline Recommendations.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- Health Care Resource Utilization and Costs for Patients with Tardive Dyskinesia.Journal of managed care & specialty pharmacy · 2019Article
- Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States.PloS one · 2019Observational
- Review
- Dopamine DNPJ schizophrenia · 2017Article
- Patterns of Antipsychotic Prescribing by Physicians to Young Children.Psychiatric services (Washington, D.C.) · 2016Article
- Delayed yet persistent effects of daily risperidone on activity in developing rats.Behavioural pharmacology · 2016Article
- Atypical antipsychotics and effects on feeding: from mice to men.Psychopharmacology · 2016Review
- Olanzapine Treatment of Adolescent Rats Alters Adult D2 Modulation of Cortical Inputs to the Ventral Striatum.The international journal of neuropsychopharmacology · 2016Article
- Incident users of antipsychotics: who are they and how do they fare?Social psychiatry and psychiatric epidemiology · 2016Article
- Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research · 2015Article
- Early-life risperidone administration alters maternal-offspring interactions and juvenile play fighting.Pharmacology, biochemistry, and behavior · 2015Article
- The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.Journal of child and adolescent psychopharmacology · 2014Article
- Review
- State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.Health services & outcomes research methodology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveThis study examined changes in the prevalence of antipsychotic medication use and the characteristics of antipsychotic users in the U.S. population between 1996 and 2005.
methodsData from the Medical Expenditure Panel Survey from 1996-1997 and 2004-2005 were used to examine the rate of first- and second-generation antipsychotic medication use and changes in the characteristics of users of all ages. Trends were examined in the level of use by antipsychotic users, both in terms of defined daily dose units and number of prescriptions.
resultsThe rate of antipsychotic use has increased substantially between 1996-1997 and 2004-2005, but the average dose measured both by defined daily dose units and number of prescriptions has remained constant. The rapid diffusion of antipsychotic medications did not occur among individuals with schizophrenia, but rather it included substantial growth among those with newer on-label conditions (such as bipolar disorder) and a high, constant rate of off-label use. Demographic, financial, and insurance characteristics of users have remained fairly constant, with few exceptions. The average age of antipsychotic users declined during the study period, because more children were using these medications in 2004-2005. However, the gender, racial, ethnic, and insurance composition of users has been fairly stable over time.
conclusionsThe rapid diffusion of second-generation antipsychotic medications was achieved by large increases in the rate of use in certain subpopulations, most notably youths. Increasing understanding about the marginal efficacy and side-effect risks of newer and more expensive antipsychotic agents, even when prescribed as indicated, suggests that the dramatic increase in use warrants careful attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.